

**FORM 51-102F3**

**Material Change Report**

**Item 1. Name and Address of Company**

Blackhawk Growth Corp. (the “Company”)  
Suite 2200, 885 West Georgia Street  
Vancouver, B.C., V6C 3E8

**Item 2. Date of Material Change**

News Release dated November 9, 2020.

**Item 3. News Release**

The Company disseminated a news release concerning the material change described herein on November 9, 2020 and subsequently filed a copy on SEDAR at [www.sedar.com](http://www.sedar.com).

**Item 4. Summary of Material Change**

Blackhawk submits SARS-CoV-2 IgG / IgM Rapid Test Kit Interim Order application and provides update on previously submitted ExProbe SARS-CoV-2 Testing Kit.

**Item 5. Full Description of Material Change**

Vancouver, British Columbia – November 9, 2020 - Blackhawk Growth Corp(CSE:BLR) (the “**Corporation**” or “**Blackhawk**”), is pleased to provide the following corporate update.

The Health Canada Interim Order (“IO”) application was completed and submitted for its **SARS-CoV-2 IgG / IgM Rapid Test Kit**. The extensive application was submitted November 4<sup>th</sup> and Health Canada confirmed receipt of the application the same day. Even though Blackhawk cannot guarantee timelines, the anticipated time to process the application is between 40 and 60 days. The **SARS-CoV-2 IgG / IgM Rapid Test Kit** currently holds Federal Drug Administration (FDA) Emergency Use Authorization (EUA) as well as a CE Mark in Europe.

About the **SARS-CoV-2 IgG / IgM Rapid Test Kit**.

### Performance Specification

Performance Indicators	Results
Runtime	15 minutes
Reproducibility / Precision	100% Concordant across 3 lots with CV±5%
Performance Comparison (A) China Validation Test (Wuhan Mobile Hospital)	Total Positive 102 / Total Negative 492 Sensitivity: 98.04% Specificity: 99.80%
Performance Comparison (B) Taiwan Validation Test (Academia Sinica)	Total Positive 39 / Total Negative 110 Sensitivity: 92.3% Specificity: 100%

*Note: Performance comparison is based on clinical samples that are COVID-19 symptomatic & previously confirmed with double qPCR tests in Taiwan & China.*

- **Intended Use:** To detect IgM and IgG antibodies against **N** and **S** protein of SARS-CoV-2 in whole blood, serum and plasma.
- **Kit Contents:** test card, diluent, capillary, lancet, and instruction for use.
- **Storage/Stability:** 2°C to 30°C for 12 months.

The **ExProbe SARS-CoV-2 TESTING KIT** Interim order application has been progressing. On October 20 2020 we received a request for additional information from Health Canada. The information they were seeking involves 3 studies to be performed, given the complexity of the studies we requested until November 13, 2020 deadline to perform and submit the requested studies. The request was granted and we are confident that timeline will be met.

In addition to the above submissions, Blackhawk was also requested to prepare for its “Health Canada Virtual Domestic Inspection of Medical Device Establishment”. In advance of the inspection, Blackhawk has review all its Standard Operating Procedures (SOP) ensuring they were updated. To date, the Corporation has submitted all required materials to Health Canada and is prepared for the inspection. The date for the inspection has not yet been confirmed.

“Busy is a severe understatement” said Frederick Pels, CEO Blackhawk. “We are pushing rapidly through the highest level of compliance and regulation in Canada. I view the requests from Health Canada as a positive and we are up to the task to meet them. We have been working on all other initiatives in tandem and will provide updates on them as soon as they become available.”

For further information please contact:  
**Frederick Pels, Chief Executive Officer**  
**(403)-991-7737**  
[fred@blackhawkgrowth.com](mailto:fred@blackhawkgrowth.com)

**.Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable

**Item 7. Omitted Information**

Not applicable

**Item 8. Executive Officer**

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels  
Chief Executive Officer  
Telephone: 403-991-7737

**Item 9.      Date of Report**

November 9, 2020